WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / April 2026 / K252424

510(k) cleared

Anti-HCV Next

Abbott Laboratories · Apr 28, 2026 · K252424

FDA cleared the Anti-HCV Next from Abbott Laboratories on Apr 28, 2026 under K252424, a traditional 510(k). The device falls under product code MZO, Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus, regulated at 21 CFR 866.3169 as a Class 2 device. The review panel was Microbiology.

FDA logged the submission as received on Aug 1, 2025. The decision came 270 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

This is the only decision on file for Abbott Laboratories in the last 12 months of the tracker.

Questions & Answers

What did FDA clear under K252424?

K252424 is the FDA 510(k) for Anti-HCV Next, submitted by Abbott Laboratories. FDA's decision date was Apr 28, 2026, under product code MZO (Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus).

Who makes the Anti-HCV Next?

Abbott Laboratories, based in Abbott Park, IL, is the applicant of record for K252424.

How long did the K252424 review take?

FDA received the submission on Aug 1, 2025 and issued its decision on Apr 28, 2026, 270 days later.

← All decisions in April 2026